KCL-286

KCL-286

• CAS Number: 1952276-71-9
• UNSPSC Description: Anticancer agent 168 is an orally active retinoic acid receptor (RAR/RXR) beta2 agonist with ameliorating effects on spinal cord injury (SCI)[1].
• Target Antigen: RAR/RXR
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
• Applications: Metabolism-sugar/lipid metabolism
• Field of Research: Others
• Assay Protocol: https://www.medchemexpress.com/anticancer-agent-168.html
• Purity: 98.93
• Solubility: DMSO : 6.25 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: CC1=CC=C(C)C2=C1OC(C3=NC(C4=CC=C(C(O)=O)C=C4)=NO3)=C2
• Molecular Weight: 334.33
• References & Citations: [1]Goncalves MB, et al. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants. Br J Clin Pharmacol. 2023 Jul 15..
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported